Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

被引:471
作者
Marcellin, P
Boyer, N
Gervais, A
Martinot, M
Pouteau, M
Castelnau, C
Kilani, A
Areias, J
Auperin, A
Benhamou, JP
Degott, C
Erlinger, S
机构
[1] HOP BEAUJON, UNITE RECH PHYSIOPATHOL HEPAT, INSERM U24, F-92118 CLICHY, FRANCE
[2] HOP BEAUJON, SERV ANAT & CYTOL PATHOL, F-92118 CLICHY, FRANCE
关键词
RNA; viral; hepatitis C-like viruses; hepatitis C; interferon-alpha; aminotransferases;
D O I
10.7326/0003-4819-127-10-199711150-00003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Less than 20% of patients with chronic hepatitis C have a sustained response to interferon-alpha therapy. The long-term benefit of interferon-alpha with regard to hepatic viral clearance and histologic improvement remains unknown. Objective: To determine the long-term biochemical, virologic, and histologic outcomes in patients with chronic hepatitis C who have a sustained response to interferon-alpha therapy. Design: Prospective cohort study. Setting: University hospital. Patients: 80 patients who had chronic hepatitis C, had a sustained biochemical and virologic response to interferon-alpha therapy, and were followed for at least 12 months. Measurements: Serum hepatitis C virus (HCV) RNA detected by polymerase chain reaction (PCR); HCV genotyping determined by line probe assay; liver histologic studies; liver HCV RNA detected by PCR on frozen liver tissue samples (in 27 patients); and repeated measurements of serum alanine aminotransferase (ALT) levels. Liver biopsy was done before treatment in all 80 patients, and at least one biopsy was done in 69 patients 1 to 6 years after treatment. Results: The 80 patients had follow-up 1 to 7.6 years (mean +/- SD, 4.0 +/- 2.0 years) after interferon-alpha treatment. The follow-up period was 1, 2, 3, 4, 5, 6, and more than 6 years in 11, 13, 14, 18, 10, 12, and 2 patients, respectively, after the end of therapy. During the entire follow-up period, 93% (95% CI, 84% to 97%) of patients had persistently normal serum ALT levels. Serum HCV RNA remained undetectable in 96% (CI, 89% to 99%) of patients, A comparison of liver histologic findings before and 1 to 6.2 years after interferon-alpha treatment showed a clear improvement in 94% (CI, 83% to 99%) of patients, In 62% of patients, the last biopsy done showed normal or nearly normal histologic findings. Liver HCV RNA was detectable before treatment in all 13 patients tested and was undetectable 1 to 5 years after treatment in all 27 patients tested. Conclusions: In patients with chronic hepatitis C who have persistently normal serum ALT levels and no detectable serum HCV RNA 6 months after interferon-alpha therapy, a long-term sustained biochemical and virologic response is generally seen. This response is associated with an absence of detectable intrahepatic HCV RNA and marked histologic improvement.
引用
收藏
页码:875 / +
页数:1
相关论文
共 28 条
[1]  
Bacon B. R., 1995, Hepatology, V22, p152A
[2]  
Benhamou J. P., 1995, Hepatology, V22, p151A
[3]   USE OF NS-4 PEPTIDES TO IDENTIFY TYPE-SPECIFIC ANTIBODY TO HEPATITIS-C VIRUS GENOTYPE-1, GENOTYPE-2, GENOTYPE-3, GENOTYPE-4, GENOTYPE-5 AND GENOTYPE-6 [J].
BHATTACHERJEE, V ;
PRESCOTT, LE ;
PIKE, I ;
RODGERS, B ;
BELL, H ;
ELZAYADI, AR ;
KEW, MC ;
CONRADIE, J ;
LIN, CK ;
MARSDEN, H ;
SAEED, AA ;
PARKER, D ;
YAP, PL ;
SIMMONDS, P .
JOURNAL OF GENERAL VIROLOGY, 1995, 76 :1737-1748
[4]   COMPARISON OF 1 OR 3 MU OF INTERFERON ALFA-2B AND PLACEBO IN PATIENTS WITH CHRONIC NON-A, NON-B HEPATITIS [J].
CAUSSE, X ;
GODINOT, H ;
CHEVALLIER, M ;
CHOSSEGROS, P ;
ZOULIM, F ;
OUZAN, D ;
HEYRAUD, JP ;
FONTANGES, T ;
ALBRECHT, J ;
MESCHIEVITZ, C ;
TREPO, C .
GASTROENTEROLOGY, 1991, 101 (02) :497-502
[5]   Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C [J].
Chemello, L ;
Cavalletto, L ;
Casarin, C ;
Bonetti, P ;
Bernardinello, E ;
Pontisso, P ;
Donada, C ;
Belussi, F ;
Martinelli, S ;
Alberti, A .
ANNALS OF INTERNAL MEDICINE, 1996, 124 (12) :1058-1060
[6]   TREATMENT OF CHRONIC HEPATITIS-C WITH RECOMBINANT INTERFERON-ALFA - A MULTICENTER RANDOMIZED, CONTROLLED TRIAL [J].
DAVIS, GL ;
BALART, LA ;
SCHIFF, ER ;
LINDSAY, K ;
BODENHEIMER, HC ;
PERRILLO, RP ;
CAREY, W ;
JACOBSON, IM ;
PAYNE, J ;
DIENSTAG, JL ;
VANTHIEL, DH ;
TAMBURRO, C ;
LEFKOWITCH, J ;
ALBRECHT, J ;
MESCHIEVITZ, C ;
ORTEGO, TJ ;
GIBAS, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) :1501-1506
[7]   RECOMBINANT INTERFERON-ALFA THERAPY FOR CHRONIC HEPATITIS-C - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
DIBISCEGLIE, AM ;
MARTIN, P ;
KASSIANIDES, C ;
LISKERMELMAN, M ;
MURRAY, L ;
WAGGONER, J ;
GOODMAN, Z ;
BANKS, SM ;
HOOFNAGLE, JH .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) :1506-1510
[8]  
DIMARTINO V, 1995, HEPATOLOGY, V22, P1216
[9]   TREATMENT OF CHRONIC NON-A,NON-B HEPATITIS WITH RECOMBINANT HUMAN ALPHA-INTERFERON - A PRELIMINARY-REPORT [J].
HOOFNAGLE, JH ;
MULLEN, KD ;
JONES, DB ;
RUSTGI, V ;
DIBISCEGLIE, A ;
PETERS, M ;
WAGGONER, JG ;
PARK, Y ;
JONES, EA .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 315 (25) :1575-1578
[10]   FORMULATION AND APPLICATION OF A NUMERICAL SCORING SYSTEM FOR ASSESSING HISTOLOGICAL ACTIVITY IN ASYMPTOMATIC CHRONIC ACTIVE HEPATITIS [J].
KNODELL, RG ;
ISHAK, KG ;
BLACK, WC ;
CHEN, TS ;
CRAIG, R ;
KAPLOWITZ, N ;
KIERNAN, TW ;
WOLLMAN, J .
HEPATOLOGY, 1981, 1 (05) :431-435